Ding XS, Mi L, Song YQ, Liu WP, Yu H, Lin NJ, Zhu J. Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report. World J Clin Cases 2021; 9(21): 6041-6048 [PMID: 34368325 DOI: 10.12998/wjcc.v9.i21.6041]
Corresponding Author of This Article
Jun Zhu, MD, PhD, Chief Doctor, Professor, Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. zhu-jun2017@outlook.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 26, 2021; 9(21): 6041-6048 Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.6041
Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report
Xiao-Sheng Ding, Lan Mi, Yu-Qin Song, Wei-Ping Liu, Hui Yu, Ning-Jing Lin, Jun Zhu
Xiao-Sheng Ding, Lan Mi, Yu-Qin Song, Wei-Ping Liu, Hui Yu, Ning-Jing Lin, Jun Zhu, Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China
Author contributions: Ding XS analyzed the data and drafted the manuscript; Mi L made substantial contributions to conception and design of the case report; Song YQ, Liu WP and Lin NJ made substantial contributions to data analysis and interpretation and critical revision of the manuscript; Yu H made substantial contributions to acquisition of the data; Zhu J provided advice for this report; and all authors have approved the final version to be published.
Informed consent statement: Written informed consent was obtained from the patient for publication of the clinical data and accompanying images.
Conflict-of-interest statement: The author reports no conflicts of interest in this work.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016) and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun Zhu, MD, PhD, Chief Doctor, Professor, Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. zhu-jun2017@outlook.com
Received: February 19, 2021 Peer-review started: February 19, 2021 First decision: April 4, 2021 Revised: April 17, 2021 Accepted: May 24, 2021 Article in press: May 24, 2021 Published online: July 26, 2021 Processing time: 129 Days and 15.7 Hours
Abstract
BACKGROUND
Academic studies have proved that anti-programmed death-1 (PD-1) monoclonal antibodies demonstrated remarkable activity in relapsed/refractory classical Hodgkin lymphoma (cHL). However, most patients ultimately experienced failure or resistance. It is urgent and necessary to develop a novel strategy for relapsed/refractory cHL. The aim of this case report is to evaluate the combination approach of low-dose decitabine plus a PD-1 inhibitor in relapsed/ refractory cHL patients with prior PD-1 inhibitor exposure.
CASE SUMMARY
The patient was a 27-year-old man who complained of enlarged right-sided cervical lymph nodes and progressive pain aggravation of the right shoulder over the past 3 mo before admission. Histological analysis of lymph node biopsy was suggestive of cHL. The patient experienced failure of eight lines of therapy, including multiple cycles of chemotherapy, PD-1 blockade, and anti-CD47 antibody therapy. Contrast-enhanced CT showed that the tumors of the chest and abdomen significantly shrunk or disappeared after three cycles of treatment with decitabine plus tislelizumab. The patient had been followed for 11.5 mo until March 2, 2021, and no progressive enlargement of the tumor was observed.
CONCLUSION
The strategy of combining low-dose decitabine with tislelizumab could reverse the resistance to PD-1 inhibitors in patients with heavily pretreated relapsed/ refractory cHL. The therapeutic effect of this strategy needs to be further assessed.
Core Tip: We report a 27-year-old man who complained of enlarged right-sided cervical lymph nodes and progressive pain aggravation of the right shoulder over the past 3 mo before admission. Histological analysis of lymph node biopsy was suggestive of classical Hodgkin’s lymphoma. The patient experienced failure of eight lines of therapy. Computed tomography showed that the tumors of the chest and abdomen significantly shrunk or disappeared after three cycles of treatment with low-dose decitabine plus tislelizumab. The patient had been followed for 11.5 mo until March 2, 2021, and no progressive enlargement of the tumor was observed.
